GHK-Cu, Melanotan II, LL-37: FDA's February 2027 Peptide Review

Last verified: 20 August 2026

FDA's Pharmacy Compounding Advisory Committee is scheduled to consider five substances before the end of February 2027: GHK-Cu, Dihexa acetate, Cathelicidin LL-37, PEG-MGF and Melanotan II. That is all that is scheduled. No date has been set, no Federal Register notice has published, and no public docket has opened.

Whatever the committee decides will not change what is legal. A PCAC vote is a recommendation. The list that governs compounding — 21 CFR 216.23 — has not been amended since 19 February 2019, holds six substances, and holds no peptides. It changes only through rulemaking, which has not begun for the July 2026 peptides, let alone these five.

How these five ended up in the queue

On 15 April 2026, FDA republished its interim list of nominated bulk drug substances and removed a group of peptides from Category 2 — the category for substances where FDA has "identified significant safety risks." The mechanism was not an FDA clearance: the nominators withdrew their nominations. That distinction is the most misreported fact here, because enforcement discretion attaches only to Category 1, so a withdrawn nomination gets none at all. Frier Levitt put it plainly — "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A." We work through the mechanics on our peptide legal status reference page.

Twelve peptides were removed. Seven — BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax and Epitalon — went to the committee on 23-24 July 2026 under Federal Register notice 2026-07361, docket FDA-2025-N-6895. The other five have not been reviewed. FDA's PCAC meetings page, content current 15 April 2026, says FDA "will host an advisory committee meeting before the end of February 2027," names all five, and says timing "will be scheduled in the coming months."

One conflict worth flagging: FDA published no Federal Register notice for the April removal. The count of twelve is trade-press sourced, and the National Law Review said seven. We could not reconcile them, because no primary document exists.

What the July 2026 precedent tells us — and what it does not

The committee recommended six of seven. Reported tallies: BPC-157, KPV and TB-500 each 8-6-1 in favor; MOTS-c 7-5-2; Semax 8-5-1; Epitalon 7-4-1; Emideltide/DSIP rejected 6-7-1. Those figures are secondary — McDermott, AJMC — because FDA has not posted minutes.

Two features bear on February. First, FDA's own review team recommended rejecting all of them: the agency's briefing document proposed not including any of the substance variants under discussion. The committee voted against its own agency's scientists six times out of seven. Second, the margins were narrow — a two-vote swing flips three of the six — and AJMC reported scrutiny of a roster that included more practitioners who prescribe or produce peptides than historical ones.

What it does not tell us is anything about legal status. No proposed rule has published. Buchanan Ingersoll & Rooney, on 18 August 2026, states the votes "did not amend the 503A Bulks List," that "there is no fixed statutory deadline within which FDA must publish a proposed or final rule," and that pharmacies "should not interpret the favorable votes as authorization to begin compounding." The prior cycle took over two years. Expect February headlines saying FDA "approved" these substances anyway — we ran the same analysis for BPC-157.

GHK-Cu: the split nobody explains

GHK-Cu is the copper(II) complex of GHK, a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — present in human plasma. It has been studied since the 1970s, largely by Loren Pickart, whose 2012 review in Oxidative Medicine and Cellular Longevity is the most-cited summary of the mechanism work. Pickart discovered the peptide, and the literature remains concentrated in one figure — the structural problem STAT found in BPC-157 research.

Three regulatory worlds, one molecule

1. Copper peptide in a cosmetic. Serums listing "copper tripeptide-1" on the panel are cosmetics — articles intended for "cleansing, beautifying, promoting attractiveness, or altering the appearance." FDA states that "cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market." The catch is claims: an article "intended to affect the structure or any function of the body" is a drug whichever aisle it sits in. A serum sold for appearance is a cosmetic; the same serum sold to rebuild collagen is an unapproved drug.

2. Compounded topical GHK-Cu. GHK-Cu is one of 47 substances in FDA's Category 1, and the entry carries a route restriction, verbatim: "GHK-Cu (except for injectable routes of administration)." Category 1 means FDA does not intend to act against a 503A compounder using it, if the interim-policy conditions are met: a §510-registered manufacturer, a valid certificate of analysis, every other 503A condition. Sheppard Mullin confirmed in June 2026 that "only GHK-Cu has been recategorized to Category 1." Discretion is agency intent — not the bulks list, and not approval.

3. Injectable GHK-Cu. Explicitly carved out of that Category 1 entry. No category, no discretion, no pathway. This is the form on the February 2027 agenda.

So a person buying a copper-peptide serum is buying a lawful cosmetic. A person given compounded topical GHK-Cu is inside the enforcement-discretion zone. A person prescribed injectable GHK-Cu is receiving a substance with no pathway at all — exposure that sits with the pharmacy and prescriber, not the patient. Marketing blurs all three by citing topical skin research beside an injection.

What the human evidence actually supports

There is a real body of GHK-Cu literature, and it is overwhelmingly in vitro fibroblast and keratinocyte work plus rodent wound models. A 2025 review in International Journal of Medical Sciences by Adnan and colleagues called the evidence "predominantly preclinical." It found a single clinical trial in scope, and that trial studied "TriHex," a tripeptide-hexapeptide combination rather than GHK-Cu alone. The review lists as an explicit limitation the "lack of clinical trial data (e.g., GHK-Cu and Pal-GHK)," and flags pharmacokinetics relevant here: plasma half-life under 30 minutes, poor skin penetration, roughly 95% excretion after dermal injection.

The honest summary is narrow. Cosmetic appearance claims for topical copper peptides rest on a small, largely industry-adjacent human literature. Systemic claims for injected GHK-Cu — body-wide tissue repair, anti-aging, hair growth — rest on preclinical work and inference. Under the FTC standard they are unsupported: the human trials have not been run.

Melanotan II: read the harm record before the agenda

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone, non-selective across melanocortin receptors MC1R to MC5R, so it acts on pigmentation, sexual function, appetite, inflammation and cardiovascular pathways at once (DermNet). It is sold grey-market for tanning and libido, with no approved indication anywhere. Its place on the docket follows from a withdrawn nomination, not from legitimacy.

What the literature and regulators describe:

• Melanoma. A 20-year-old woman with Fitzpatrick type II skin developed histologically confirmed melanoma after a three-to-four-week course of self-injected melanotan-II — Hjuler KF, Lorentzen HF. Dermatology. 2014;228(1):34-6, PMID 24355990.
• Rhabdomyolysis and renal dysfunction. A 39-year-old man self-injected internet-purchased melanotan II at six times the vendor's suggested amount; creatine phosphokinase reached 17,773 IU/L at twelve hours — Nelson ME, et al. Clin Toxicol. 2012;50(10):1169-73, PMID 23121206.
• Eruptive dysplastic nevi, in JAAD, Actas Dermo-Sifiliográficas and the British Journal of Dermatology.
• Mole darkening and new mole formation, melanonychia, nausea and vomiting, priapism and spontaneous erections lasting one to five hours, and contamination from improper preparation (DermNet).

Several national regulators have warned about it. Cancer Research UK states that "it is illegal to sell and supply Melanotan injections in the UK" and that the products "have not been tested for safety, quality or effectiveness." Australia's Therapeutic Goods Administration has issued safety alerts on inconsistently dosed product. In the United States the enforcement record is not hypothetical: the Department of Justice announced in March 2015 that the former owner and employees of Melanocorp Inc. pleaded guilty to federal charges including conspiring to defraud FDA, over a product the release calls "a drug that had not been approved by the FDA."

Cathelicidin LL-37

LL-37 is the only human cathelicidin: an endogenous antimicrobial peptide produced by neutrophils and epithelial cells, with real roles in innate immunity, chemotaxis and wound repair. In wellness marketing it is sold, usually as an injection, for immune support, chronic infection, biofilm and gut complaints.

The human trial evidence exists, and it is topical wound care. A randomized placebo-controlled study in hard-to-heal venous leg ulcers concluded that topical LL-37 "was safe and well tolerated with the marked effect on healing predictors at the two lower doses warranting further investigations" — Grönberg A, et al. Wound Repair Regen. 2014;22(5):613-621. The larger follow-up did not replicate it. A phase IIb trial in 148 treated patients missed its primary endpoint of confirmed wound closure at 13 weeks — 26.5% and 24.7% in the two LL-37 arms versus 25.3% on placebo. The authors wrote that it "did not detect any significant differences in healing of venous lower leg ulcers in the entire study cohort comparing patients treated with LL-37 versus placebo" (Mahlapuu M, et al. Wound Repair Regen. 2021;29(6):938-950, PMID 34687253).

A competent human program, topical, negative on its primary endpoint. We located no controlled trial of injected LL-37 for the uses it is marketed for. It is in no FDA category and cannot lawfully be compounded.

Dihexa acetate

Dihexa is a metabolically stabilized analogue of angiotensin IV, developed at Washington State University and designed to cross the blood-brain barrier. It is marketed for cognitive enhancement, memory and "neuroplasticity."

The human data are not thin. They are absent. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality report, updated 13 August 2021, states that "no studies in humans have been published to date." The supporting work is in rodents. The same report identifies the safety problem built into the mechanism: dihexa promotes hepatocyte growth factor / c-Met signaling, and "activation of HGF and c-Met is a key signaling pathway in many cancers." It adds that "no studies have tested the long-term safety of dihexa treatment including its potential effects on tumorigenesis." The nearest human test of that pathway for cognition — Athira Pharma's fosgonimeton, a different molecule, in 312 Alzheimer's patients — missed its primary endpoint in September 2024.

PEG-MGF

Mechano growth factor is a splice variant of insulin-like growth factor 1 — IGF-1Ec — expressed in skeletal muscle in response to mechanical loading (PLOS One, 2013). PEG-MGF is a pegylated form with a longer half-life, marketed for muscle repair, recovery and hypertrophy.

Its regulatory position differs from the other four. Mechano growth factor appears in FDA's Category 3 — nominated with insufficient information for FDA to evaluate. Category 3 has the same effect as Category 2: FDA would consider acting against a compounder using it. The pegylated form under review left Category 2 in April 2026 and is now in no category.

On the sport axis this one is unambiguous. WADA section S2.3 (Growth Factors) explicitly names mechano growth factors alongside IGF-1, FGFs, HGF, PDGF and VEGF, and the 2026 Prohibited List took effect on 1 January 2026. A pegylated MGF falls within that class. Legality and doping status are independent axes: a substance can be prohibited in sport while lawfully prescribed.

The five at a glance

What to watch, and where to check it yourself

• FDA's PCAC meetings page — where a February date appears first. Today it still reads "before the end of February 2027."
• FDA's advisory committee calendar — fda.gov/advisory-committees/advisory-committee-calendar. Rosters and briefing materials post here, the latter no later than two business days before a meeting.
• The Federal Register — this FDA search returns every compounding bulk-substance document. Look for a meeting notice opening a docket for the five (none yet), and a proposed rule amending 21 CFR 216.23 (none yet). The proposed rule is the one that matters.
• Regulations.gov — the July docket is FDA-2025-N-6895, closed 22 July 2026. A new number will be assigned for February.

The outstanding gap. FDA has still not published minutes or a transcript from July 2026. The meeting page, content current 6 August 2026, holds the agenda, roster, briefing materials and presentations — no minutes, no transcript. Every vote tally in circulation, including ours, is secondary reporting.

We will update this page

This page is published six months ahead of the review window on purpose. We check the meetings page and calendar weekly, and will add a dated entry when:

• FDA sets a date for the meeting.
• A Federal Register notice publishes — we will add the document number, docket number and comment deadline.
• FDA posts briefing materials. These matter more than the vote: they carry FDA's own scientific assessment, and in July FDA's reviewers recommended rejecting everything.
• Votes are taken, marked as secondary reporting or official record — and when the July 2026 minutes appear, we reconcile the tallies above.
• A proposed rule publishes amending 21 CFR 216.23 — the first real change in legal status since 2019.

Frequently asked questions

Is GHK-Cu legal?

It depends on the form. A copper-peptide cosmetic making appearance claims is lawfully marketed and needs no FDA approval. Topical GHK-Cu compounded by a 503A pharmacy sits in Category 1 — enforcement discretion, if the conditions are met. Injectable GHK-Cu is excluded from that entry and cannot lawfully be compounded.

What is GHK-Cu's FDA status?

Not FDA-approved in any form. FDA's category list of 14 May 2026 reads "GHK-Cu (except for injectable routes of administration)" in Category 1. The injectable route goes to the committee before the end of February 2027. Category 1 is interim policy, not the law.

Is melanotan 2 legal in the US?

No. It is not approved here or anywhere, is not on the bulks list, and is in no FDA category. Distributing it has produced federal criminal convictions. Enforcement runs against sellers, not buyers, but a user's real exposure is clinical — see the harm record above.

Is LL-37 legal?

No. It is in no FDA category, is not on the bulks list, and is not FDA-approved, so a 503A pharmacy cannot lawfully compound it. A favorable February recommendation would not by itself change that.

When is the next FDA peptide review?

Before the end of February 2027. No date set as of 20 August 2026, no Federal Register notice, no open docket. The agenda: GHK-Cu, Dihexa acetate, Cathelicidin LL-37, PEG-MGF and Melanotan II.

If the committee votes yes, can I get these prescribed?

Not on the strength of the vote. FDA would still have to publish a proposed rule, take comment, and finalize an amendment to 21 CFR 216.23. The last cycle took over two years, and no deadline forces FDA to act. Bulks-list inclusion is also not a finding that a substance is safe or effective.

This is consumer research about how peptides are regulated and sold. It is not medical advice, and we are not your doctor. Nothing here should be used to start, stop or change any treatment. Talk to a licensed clinician who knows your history.